🔎 Trials Near Me

Home › Neuroendocrine Carcinoma › Missouri

Neuroendocrine Carcinoma clinical trials in Missouri

3 studies for Neuroendocrine Carcinoma are looking for participants at sites in Missouri.

Cities in Missouri

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  • Washington University Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Washington University School of Medicine (Siteman Cancer Center), St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • Washington University Infusion Center Pharmacy, St Louis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.